Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments
This study presented the first real-world data with galcanezumab in Brazilian patients with CH and showed a reduction in headache frequency in most patients. A survey of Brazilian experts not meant to represent the country's guidelines, favored galcanezumab as either the first or the second option in prophylaxis. Collectively, these results highlighted galcanezumab's promising efficacy as a new tool in CH patients.
Authors
- Carla Jevoux (ORCID: https://orcid.org/0000-0003-4344-1028)
- Pedro André Kowacs (ORCID: https://orcid.org/0000-0001-7770-7475)
- Carlos Alberto Bordini (ORCID: https://orcid.org/0000-0002-1249-5202)
- Fabíola Dach (ORCID: https://orcid.org/0000-0003-4249-4179)
- Abouch Valenty Krymchantowski (ORCID: https://orcid.org/0000-0001-8164-3507)
- Marcelo Moraes Valênça (ORCID: https://orcid.org/0000-0003-0678-3782)
- Paulo Hélio Monzillo
- Élcio Juliato Piovesan (ORCID: https://orcid.org/0000-0002-0915-0430)
- Raimundo Pereira Silva‐Néto (ORCID: https://orcid.org/0000-0002-2343-9679)
- Fernando Kowacs (ORCID: https://orcid.org/0000-0002-0407-407X)
Institutions
- Universidade de Ribeirão Preto (BR)
- Universidade de São Paulo (BR)
- Universidade Federal de Pernambuco (BR)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- Hospital Israelita Albert Einstein (BR)
- Universidade Federal do Piauí (BR)
- Hospital Moinhos de Vento (BR)
- Hospital Geral de Bonsucesso (BR)
- Instituto de Neurologia de Curitiba (BR)
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1186/s10194-024-01909-w
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.54